Ocuphire Shares Rally Premarket as FDA Approves Ryzumvi Eye Drops
27 Setembro 2023 - 9:58AM
Dow Jones News
By Colin Kellaher
Shares of Ocuphire Pharma rose sharply in premarket trading
Wednesday after the ophthalmic biopharmaceutical company and
partner Viatris won U.S. Food and Drug Administration approval of
their Ryzumvi eye drops.
Ocuphire and Viatris on Wednesday said the approval covers
Ryzumvi for the treatment of pharmacologically-induced mydriasis
produced by adrenergic agonists or parasympatholytic agents.
Ocuphire, based in Farmington Hills, Mich., last year inked a
licensing agreement for the development and commercialization of
Ryzumvi with FamyGen Life Sciences, which healthcare company
Viatris acquired earlier this year.
Ocuphire and Viatris said they expect Ryzumvi to be commercially
available in the U.S. in the first half of 2024.
Shares of Ocuphire, which closed Tuesday at $4.02, were recently
up 9.5% to $4.40 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 27, 2023 08:43 ET (12:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Viatris (NASDAQ:VTRS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Viatris (NASDAQ:VTRS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
